Trials / Unknown
UnknownNCT04633733
The Study of Pharmacokinetic Interactions Between HL237 and Tacrolimus
An Open-label, Multiple-dose, Fixed-sequence, 3-Period Study to Evaluate the Pharmacokinetic Interactions Between HL237 and Tacrolimus in Healthy Male Subjects
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Hanlim Pharm. Co., Ltd. · Industry
- Sex
- Male
- Age
- 19 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
This study aims to evaluate the pharmacokinetic interaction between HL237 and tacrolimus in healthy male subjects.
Detailed description
To evaluate the pharmacokinetic interaction by comparing of pharmacokinetic parameters when administered HL237(or tacrolimus) between with tacrolimus(or HL237) and without tacrolimus(or HL237).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HL237 tablet | HL237 400mg will be administered orally twice a day. |
| DRUG | tacrolimus capsule | tacrolimus 5mg will be administered orally once a day. |
Timeline
- Start date
- 2020-08-22
- Primary completion
- 2020-09-24
- Completion
- 2021-01-01
- First posted
- 2020-11-18
- Last updated
- 2020-11-18
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04633733. Inclusion in this directory is not an endorsement.